GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

Back to Search
Print
Bookmark Trial

NCT00373685

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Abbeville, Alabama, 36310, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55-99 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patients of at least 55 years of age with a clinical diagnosis of OA who are expected to require daily prescription anti-inflammatory analgesic therapy for arthritis symptom management and for whom either celecoxib or a nsNSAID is an appropriate treatment option.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- GI ulcer hemorrhage or active GD ulceration less than 90 days prior to screening
visit.


- Patients with a history of myocardial infarction, unstable angina, ischemic or
hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to
coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

OsteoarthritisStudy Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement NCT00454298
  1. Boston, Massachusetts
  2. Boston, Massachusetts
  3. Newton, Massachusetts
  4. Winchester, Massachusetts
  5. Worcester, Massachusetts
ALL GENDERS
55 Years+
years
MULTIPLE SITES
OsteoarthritisClinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee NCT01102660
  1. Paramount, California
  2. Spring Valley, California
  3. Valley Village, California
  4. Daytona Beach, Florida
  5. Ormond Beach, Florida
  6. Plantation, Florida
  7. Plantation, Florida
  8. South Miami, Florida
  9. Gurnee, Illinois
  10. Overland Park, Kansas
  11. Overland Park, Kansas
  12. Overland Park, Kansas
  13. Prairie Village, Kansas
  14. Wichita, Kansas
  15. Fall River, Massachusetts
  16. Hyannis, Massachusetts
  17. New Bedford, Massachusetts
  18. St. Louis, Missouri
  19. Rochester, New York
  20. Wilmington, North Carolina
  21. Kettering, Ohio
  22. Pawtucket, Rhode Island
  23. Mt. Pleasant, South Carolina
  24. New Tazewell, Tennessee
  25. Dallas, Texas
  26. San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
OsteoarthritisA Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain NCT00418782
  1. Anniston, Alabama
  2. Bayou La Batre, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Hot Springs, Arkansas
  7. Northridge, California
  8. Sacramento, California
  9. Tarzana, California
  10. Denver, Colorado
  11. Denver, Colorado
  12. Westminster, Colorado
  13. Clearwater, Florida
  14. DeFuniak Springs, Florida
  15. Destin, Florida
  16. Pensacola, Florida
  17. Chicago, Illinois
  18. Gurnee, Illinois
  19. Avon, Indiana
  20. Indianapolis, Indiana
  21. Gretna, Louisiana
  22. Kenner, Louisiana
  23. Metairie, Louisiana
  24. Baltimore, Maryland
  25. Frederick, Maryland
  26. Flowood, Mississippi
  27. Columbia, Missouri
  28. Kansas City, Missouri
  29. Missoula, Montana
  30. Trenton, New Jersey
  31. Beavercreek, Ohio
  32. Cincinnati, Ohio
  33. Kettering, Ohio
  34. Ashland, Oregon
  35. Eugene, Oregon
  36. Duncansville, Pennsylvania
  37. Summerville, South Carolina
  38. Collierville, Tennessee
  39. Knoxville, Tennessee
  40. Memphis, Tennessee
  41. Bryan, Texas
  42. Longview, Texas
  43. San Antonio, Texas
  44. San Antonio, Texas
  45. Arlington, Virginia
  46. Spokane, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
OsteoarthritisMeasuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib. NCT00484718
  1. Palo Alto, California
  2. Stanford, California
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
Official Title  ICMJE Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In Osteoarthritis Patients
Brief Summary This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis
Intervention  ICMJE
  • Drug: Celecoxib
    open-label
  • Drug: Any commercially available NSAID with the indication for osteoarthritis
    dosing as per USPI label related to the chosen commercially marketed NSAID
Study Arms  ICMJE
  • Experimental: Celecoxib
    dosing as per USPI label
    Intervention: Drug: Celecoxib
  • Active Comparator: NSAIDs
    Intervention: Drug: Any commercially available NSAID with the indication for osteoarthritis
Publications * Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013 Mar;108(3):392-400. doi: 10.1038/ajg.2012.467. Epub 2013 Feb 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 26, 2011)		8067
Original Enrollment  ICMJE
 (submitted: September 7, 2006)		8000
Actual Study Completion Date  ICMJE November 2010
Actual Primary Completion Date November 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female patients of at least 55 years of age with a clinical diagnosis of OA who are expected to require daily prescription anti-inflammatory analgesic therapy for arthritis symptom management and for whom either celecoxib or a nsNSAID is an appropriate treatment option.

Exclusion Criteria:

  • GI ulcer hemorrhage or active GD ulceration less than 90 days prior to screening visit.
  • Patients with a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 55 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00373685
Other Study ID Numbers  ICMJE A3191331
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP